A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

Trial Profile

A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jun 2012 Results are to be presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a UCB media release.
    • 13 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00993317).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top